Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy

NCT06133517 is registered in ClinicalTrials.gov with Fundación para el Progreso de la Oncología en Cantabria as lead sponsor.

NCT NCT06133517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06133517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy
Lead sponsor
Fundación para el Progreso de la Oncología en Cantabria
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 20, 2025
Completion date
December 31, 2030
Enrollment
70 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial bladder carcinoma